A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Inclusion Criteria

• •1. Patient age is greater than or equal to 18 years
• •2. Patient has a history of histologically confirmed classical HL (i.e. Nodular sclerosing (NSHL), Mixed-cellularity (MCHL), Lymphocyte-rich (LRHL), Lymphocyte depleted (LDHL))
• •3. Patient has achieved a complete response by CT/MRI scan within 9 weeks (± 1 week) from the day of their first autologous peripheral blood/ bone marrow stem cell transfusion (AHSCT) following HDT. Complete response is defined as:
• •Normalization of all nodes and lesions compared to pre-transplant scan performed prior to salvage therapy for relapse. Any residual abnormal masses on the post transplant CT/MRI must be metabolically inactive on a PET scan.
• •4. Patient has at least one of the following factors that places them at risk for relapse:
• •* Primary refractory disease (including relapse in ≤ 3 months of completion of 1st line treatment)
• •* First relapse \>3 but \<12 months from last dose of 1st line treatment
• •* Multiple relapses (prior to transplant)
• •* Stage III/IV disease (at relapse, prior to transplant)
• •* Hemoglobin \<10.5 gm/dL (at relapse, prior to transplant)